Batch review brief
Execution is complete. Two review items need attention.
Product-impact assessment
DEV-038 does not yet establish the product impact of the transfer interruption.
Complete QC panel
QC-2407 supplies SEC purity. BR-012 also requires potency and host cell protein. Missing from this package does not mean the tests were not performed.
Review basis and selected versions
Checked against the supplied BR-012 v06 excerpt. This brief is not an exhaustive batch-release checklist.
Selected snapshots: 9 September 2026, 09:00 UTC. Original source versions stay attached to this brief.
Follow-up work by owner
- QC reviewer
- Supply the potency and host cell protein reports for B-2407. Confirm sample and batch identity, applicable methods and specifications, report review status and any exceptions.
- Deviation owner
- Complete the product-impact assessment in DEV-038 using the transfer pump log, line pressure trend and post-transfer bioburden result; route it to the authorised reviewer.
- QA reviewer
- Confirm the complete batch-review scope and assess the execution, analytical and deviation evidence. Refresh source statuses before recording any disposition; preserve required signatures and the stock restriction until the authorised process permits a change.
